


CST626

Cat. No.:	HY-149924		
Molecular Formula:	C ₆₁ H ₈₂ N ₈ O ₉ S		
Molecular Weight:	1103.42		
Target:	PROTACS; IAP		
Pathway:	PROTAC; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (90.63 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		0.9063 mL	4.5314 mL	9.0627 mL
		5 mM		0.1813 mL	0.9063 mL	1.8125 mL
10 mM		0.0906 mL	0.4531 mL	0.9063 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (2.27 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (2.27 mM); Clear solution; Need ultrasonic Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (2.27 mM); Clear solution; Need ultrasonic 					

BIOLOGICAL ACTIVITY

Description	CST626 (Compound 9) is a pan-IAP degrader PROTAC. PROTAC pan-IAP degrader-1 degrades XIAP, cIAP1 and cIAP2 with DC ₅₀ s of 0.7, 2.4, and 6.2 nM in MM.1S cells, respectively ^[1] .
In Vitro	<p>CST626 (Compound 9) induces cIAP1, cIAP2 and XIAP degradation in a dose-dependent manner with DC₅₀ values of 2.4 nM, 6.2 nM, and 0.7 nM, respectively^[1].</p> <p>CST626 (0-10 μM; 96 h) shows potent inhibition of cancer cell viability^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p>

Cell Line:	MM.1S cells
Concentration:	0.0001, 0.001, 0.01, 0.1 and 1 μ M
Incubation Time:	16 h
Result:	Revealed DC ₅₀ values of 2.4 nM (cIAP1), 6.2 nM (cIAP2), and 0.7 nM (XIAP).

Cell Viability Assay^[1]

Cell Line:	SUDHL6, MOLM13, NCI-H929, K562, DB, JJN3, HEL, SUDHL4 and RPMI-8826 cells
Concentration:	0.01, 0.04, 0.1, 0.4, 1, 4 and 10 μ M
Incubation Time:	96 h
Result:	Inhibited cell viability with IC ₅₀ s of 0.0016, 0.0021, 0.0085, 0.42, 0.46, 1.14, 1.17, 1.69 and 2.54 μ M against SUDHL6, MOLM13, NCI-H929, K562, DB, JJN3, HEL, SUDHL4 and RPMI-8826 cells, respectively.

REFERENCES

[1]. Ng YLD, et al. Heterobifunctional Ligase Recruiters Enable pan-Degradation of Inhibitor of Apoptosis Proteins. J Med Chem. 2023 Apr 13;66(7):4703-4733.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA